Aprepitant plus ondansetron may increase acute-CR , may have benefit regarding CINV 's effect on QoL , and is safe for 5-day temozolomide compared to ondansetron .
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists. Antiemetic research with aprepitant has routinely excluded glioma patients. In this randomized open-label phase II study, use of a nonstandard 5-day regimen of aprepitant for glioma patients was investigated. ### methods One hundred thirty-six glioma patients receiving their first cycle of adjuvant temozolomide (150-200 mg/m ### results Patients were 61% male, 97% white, 48% with KPS > 90%, 60% non-smokers, mean age 54, 92% with low alcohol use, and 46% with a CINV history. The CC was 58.6% (Arm-A) and 54.5% (Arm-B). Acute-complete response (CR) rates, defined as CC on day 1 in Arm-A and -B, were 97.1% and 87.9%, respectively (p = 0.056). Treatment-related toxicities were mild or moderate in severity. ### conclusions Aprepitant plus ondansetron may increase acute-CR , may have benefit regarding CINV 's effect on QoL , and is safe for 5-day temozolomide compared to ondansetron . This study provides no evidence that aprepitant increases CC rate over ondansetron alone.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists. Antiemetic research with aprepitant has routinely excluded glioma patients. In this randomized open-label phase II study, use of a nonstandard 5-day regimen of aprepitant for glioma patients was investigated. ### methods One hundred thirty-six glioma patients receiving their first cycle of adjuvant temozolomide (150-200 mg/m ### results Patients were 61% male, 97% white, 48% with KPS > 90%, 60% non-smokers, mean age 54, 92% with low alcohol use, and 46% with a CINV history. The CC was 58.6% (Arm-A) and 54.5% (Arm-B). Acute-complete response (CR) rates, defined as CC on day 1 in Arm-A and -B, were 97.1% and 87.9%, respectively (p = 0.056). Treatment-related toxicities were mild or moderate in severity. ### conclusions Aprepitant plus ondansetron may increase acute-CR , may have benefit regarding CINV 's effect on QoL , and is safe for 5-day temozolomide compared to ondansetron . This study provides no evidence that aprepitant increases CC rate over ondansetron alone.

            ### Response:
            Aprepitant, ondansetron, temozolomide, ondansetron
            